Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographic and clinical characteristics of the healthy control and disease groups

From: Serum bone-turnover biomarkers are associated with the occurrence of peripheral and axial arthritis in psoriatic disease: a prospective cross-sectional comparative study

At blood sampling HC (n = 50) PsC (n = 200) pPsA (n = 127) PsSpA (n = 117) AS (n = 157)
Median (IQR) Median (IQR) Median (IQR) Median (IQR) Median (IQR)
Age (years) 59.93 (51.44, 67.56) 54 (42, 65) 58.45 (50.31, 66.63) 59.53 (59.56, 66.54) 54.70 (44.52, 63.41)
Disease duration (years) n/a 24 (16, 36.5) 15 (7, 26) 18 (9, 27) 22 (10, 31)
BMI (kg/m2) n/a n/a 29.04 (26.30, 32.84) 28.56 (26.06, 31.98) 27.07 (24.58, 30.13)
CRP (mg/dL) n/a n/a 2 (0, 5) 3 (2, 7) 4 (1, 10)
ASDAS (units) n/a n/a 2.1 (1.3, 2.7) 2.2 (1.5, 2.9) 2.1 (1.6, 2.9)
PASI (units) n/a 4.8 (2.4, 8.8) 0.8 (0.0, 2.6) 0.8 (0.0, 2.8) n/a
  n (%) n (%) n (%) n (%) n (%)
Male sex 26 (52.00) 102 (51.00) 66 (51.97) 74 (63.25) 118 (75.16)
Anti-TNF use n/a 26 (13.00) 47 (37.01) 53 (45.30) 59 (37.58)
HLA-B27 positive n/a n/a 9 (7.09) 47 (40.17) 140 (89.17)
  1. HC healthy control, PsC psoriasis without arthritis, pPsA peripheral PsA, PsSpA psoriatic spondyloarthropathy, AS ankylosing spondylitis, IQR interquartile range, n number/proportion, n/a not available/applicable, BMI body mass index, CRP C-reactive protein, ASDAS AS Disease Activity Score, PASI Psoriasis Area Severity Index, HLA human leucocyte antigen, Anti-TNF anti-tumour necrosis factor drug, sDMARD synthetic disease modifying anti-rheumatic drug